Clinical Trials Logo

Pulmonary Sarcoidosis clinical trials

View clinical trials related to Pulmonary Sarcoidosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05247554 Not yet recruiting - Clinical trials for Pulmonary Sarcoidosis

Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis

QUIDOSE
Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

"The reference treatment for pulmonary sarcoidosis is prolonged systemic corticosteroid therapy, which improves dyspnea, fatigue and respiratory function. However, corticosteroid therapy doesn't improve quality of life, possibly due to its adverse effects. Furthermore, in an international survey study, the first priority in treatment outcome for sarcoidosis patient was quality of life. Hydroxychloroquine an antimalarial drug, has been shown to be effective in cutaneous and pulmonary forms of sarcoidosis but in studies with imperfect methodology. Our hypothesis is that hydroxychloroquine associated with low-dose corticosteroids improves lung function as much as ""conventional"" medium-dose corticosteroid therapy but with fewer side effects and a better quality of life in pulmonary sarcoidosis. "